Cardionerds: A Cardiology Podcast cover image

306. Decompensated Right Ventricular Failure in Pulmonary Arterial Hypertension with Dr. Mardi Gomberg-Maitland and Dr. Rachel Damico

Cardionerds: A Cardiology Podcast

00:00

The Different Pathways for Treatment of Pulmonary Artery Hypertension

There are three pathways that we can approach with FDA approved drugs for pulmonary arterial hypertension. PD5 inhibitors represent one of the calming classes and again, probably the most common use drugs were the PDE5 inhibitors. The second pathway we target is the endothelion pathway. There's too much endothelion one when patients have pulmonary chiral hypertension. Inelational drugs like Taebeso have to be delivered to a specialized device.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app